With low dose starting at 1,290 per month, analysts are expecting a two-fold jump in the sale of GLP-1 units over the next three months due to the steep price cuts.

Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, on Saturday announced the launch of its injectable semaglutide under the brand name Obeda®, marking an important step in expanding ...

Dr Reddy's Laboratories has announced the launch of its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to GLP-1 receptor agonist-based therapy for the ...

Looking to enter India’s ₹1,446 crore glucagon-like peptide (GLP-1) market, Hyderabad-based pharma major Dr Reddy’s Laboratories (DRL) has launched its semaglutide generic, Obeda, for Type 2 diabetes ...

Pharmaceutical major Dr. Reddy''s Laboratories Ltd on Saturday announced the launch of its injectable semaglutide under the brand name Obeda, a type 1 diabetes drug in India.

Generic drugmakers in India launch affordable Semaglutide versions, targeting a $1 billion diabetes and weight loss market.

Researchers developed a chip-based platform, “μPharma,” that rapidly predicts drug response through AI analysis for children ...

Key Takeaways. LGM Pharma’s Texas expansion targets commercial suppository manufacturing and broader semi-solid/liquid ...

Sun Pharma to Dr Reddy's and Lupin are gearing up to launch over 50 brands that will compete with Ozempic, Wegovy and Mounjaro at half the price.

CDSCO asks SLAs to cancel product permission to sodium hyaluronate eye drops 0.3% w/v: Gireesh Babu, New Delhi Friday, March 20, 2026, 08:00 Hrs [IST] The Central Drugs Standard C ...

BOCA RATON, Fla.-- (BUSINESS WIRE)--March 19, 2026-- ...

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug conjugates, will ...